Scalper1 News
Big pharma Bristol-Myers Squibb (BMY) said Friday that it’s selling its HIV drug pipeline to ViiV Healthcare, a company majority-owned by GlaxoSmithKline (GSK), in two transactions worth up to $2.9 billion. ViiV agreed to pay $350 million upfront for two clinical-stage products, one in late phase-two testing and other in phase three, along with a number of preclinical and discovery programs. Bristol-Myers can receive up to $518 million in Scalper1 News
Scalper1 News